Breakthrough in chronic kidney disease: solid hammer new drug can effectively protect renal function and prolong life span

The results of the study just released at the 2020 European Academic Conference on heart disease. The results showed that on the basis of standard treatment, daggliptin could further reduce renal function deterioration, kidney and cardiovascular death events by 39%, and reduce all-cause mortality by 31%. < / P > < p > this study is a phase III clinical trial of dapglitazin in the treatment of nephropathy, involving 4304 patients with nephropathy. The glomerular filtration rate (GFR) of the patients ranged from 25 to 75, which had been fully treated with pril / sartans. Among them, 32.5% patients did not have diabetes. < p > < p > the patients were randomly divided into two groups: dapagliptin group and placebo group. The daggliptin group was treated with one tablet daily, while the placebo group was treated with placebo. Neither the doctor nor the patient knows who is taking the drug or the placebo. < / P > < p > it is planned to end the follow-up when 681 patients reach the end point. The main composite endpoint is deterioration of renal function or death of kidney and cardiovascular system. According to the original plan, this study is expected to take 4 years. However, after a median follow-up of only 2.4 years, the study was terminated early in March this year due to the overwhelming efficacy of the treatment group. < p > < p > the results showed that: for patients with renal insufficiency who had not progressed to uremia, whether with or without type 2 diabetes mellitus, compared with placebo, daseglinin could further reduce the composite endpoint by 39% and significantly reduce the risk of all-cause death by 31%. The renal protective effect of linegin drugs was twice as high as that of sartans, and could not be used completely Hypoglycemic to explain. The dapa-ckd study also confirmed that the benefit of dagglitazin treatment was the same regardless of whether the patients were complicated with diabetes or not. < p > < p > dapagliptin belongs to the class of drugs called “sodium glucose transporter 2 inhibitor” – what does this strange name mean? In the renal tubules of our kidney, there is a protein called “sodium glucose transporter”, which is responsible for reabsorbing sugar and sodium in renal tubules back into the body, so as not to let blood sugar lose. Type 2 reabsorbed sugar accounted for 90%. In diabetic patients, sodium glucose transporter 2 absorbed more sugar than healthy people. < / P > < p > if we try to suppress sodium glucose transporter 2 and prevent it from reabsorbing so much sugar, won’t sugar be excreted through the kidney? This achieves the effect of lowering blood sugar. < p > < p > Liejing drugs can excrete about 80g glucose every day, which is equivalent to taking away the heat of two steamed bread or a bowl of rice, so as to achieve the effect of weight loss. The smart reader must have thought: look at the name of “sodium glucose transporter 2”, will it reabsorb sodium? If we inhibit the reabsorption of sodium, we can get it out of the body. If you don’t have enough sodium, your blood pressure will drop – and yes, levulinids can also lower your blood pressure. When the blood glucose and sodium are discharged, the glomerular pressure will be reduced, the feedback of the bulbar tube will be restored, and the process of renal failure will be slowed down, so as to achieve the effect of protecting the kidney. In addition, the protective effects of lejing drugs are also manifested in improving renal tissue hypoxia, reducing renal inflammation and fibrosis, and reducing urinary protein and protecting renal function through multiple ways. < p > < p > nine years ago, as a hypoglycemic drug, Lijing drugs came into being, and it was still a kind of hypoglycemic drugs that were not very promising at that time. But in just a few years, great changes have taken place. The advantages of such drugs have sprung up after a spring rain and become the best hypoglycemic drugs. < / P > < p > they are no longer just hypoglycemic drugs. The drug has become a kidney protecting drug and an anti heart failure drug. Although the progress of engliptin and caglitazin is a little slow, it is also reported frequently in many disease areas, and even the drugs of geneticin are expected to become a new class of antihypertensive drugs. Small habits of pregnancy not only affect the health of pregnant mother, but also delay the development of the fetus, don’t ignore